Literature DB >> 19776380

Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP.

M Iijima1, M Tomita, S Morozumi, Y Kawagashira, T Nakamura, H Koike, M Katsuno, N Hattori, F Tanaka, M Yamamoto, G Sobue.   

Abstract

OBJECTIVE: Chronic inflammatory demyelinating polyneuropathy (CIDP) is characterized by immune-mediated peripheral demyelination. Although corticosteroid, IV immunoglobulin (IVIg) and plasma exchange have been established as the most effective therapeutics, subpopulations of patients show little or no response to either of these therapies. In this study, we examined whether particular genetic factors influence the therapeutic responsiveness of patients with CIDP.
METHODS: One hundred Japanese patients categorized as responders or nonresponders to IVIg therapy participated in our study. We performed an association analysis with single nucleotide polymorphisms (SNPs) and haplotype studies between the IVIg responders and nonresponders.
RESULTS: Two separate SNPs, corresponding to TAG-1 (transient axonal glycoprotein 1) and CLEC10A (C-type lectin domain family 10, member A), showed strong significant differences between responders and nonresponders. Haplotype analysis of a series of expanded SNPs, from TAG-1 or CLEC10A, showed that only TAG-1 included a significant haplotype within 1 linkage disequilibrium block, which accommodates IVIg responsiveness. Diplotype analysis of TAG-1 also supported this observation.
CONCLUSIONS: Transient axonal glycoprotein 1 is a crucial molecule involved in IV immunoglobulin responsiveness in Japanese patients with chronic inflammatory demyelinating polyneuropathy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19776380     DOI: 10.1212/WNL.0b013e3181bd1139

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

Review 1.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

2.  Early predictive factors of disability in CIDP.

Authors:  Emanuele Spina; Antonietta Topa; Rosa Iodice; Stefano Tozza; Lucia Ruggiero; Raffaele Dubbioso; Marcello Esposito; Dario Bruzzese; Lucio Santoro; Fiore Manganelli
Journal:  J Neurol       Date:  2017-08-02       Impact factor: 4.849

Review 3.  Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.

Authors:  Jan D Lünemann; Falk Nimmerjahn; Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2015-01-06       Impact factor: 42.937

Review 4.  Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders.

Authors:  Panos Stathopoulos; Harry Alexopoulos; Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2015-01-27       Impact factor: 42.937

5.  Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins.

Authors:  Mohamed Mahdi-Rogers; Yusuf A Rajabally
Journal:  Biologics       Date:  2010-03-24

Review 6.  Efficacy of Intravenous Immunoglobulin in Neurological Diseases.

Authors:  Jan D Lünemann; Isaak Quast; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 7.  Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variants.

Authors:  Mazen M Dimachkie; Richard J Barohn; Jonathan Katz
Journal:  Neurol Clin       Date:  2013-02-16       Impact factor: 3.806

8.  Contactin-2/TAG-1, active on the front line for three decades.

Authors:  Tomoyuki Masuda
Journal:  Cell Adh Migr       Date:  2017-01-31       Impact factor: 3.405

9.  Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.

Authors:  Tomohiro Hayashi; Takamasa Nukui; Jin-Lan Piao; Tomoyuki Sugimoto; Ryoko Anada; Noriyuki Matsuda; Mamoru Yamamoto; Hirofumi Konishi; Nobuhiro Dougu; Yuji Nakatsuji
Journal:  Brain Behav       Date:  2021-02-22       Impact factor: 2.708

Review 10.  Pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy: Insights into Classification and Therapeutic Strategy.

Authors:  Haruki Koike; Masahisa Katsuno
Journal:  Neurol Ther       Date:  2020-05-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.